The Economic Impact of Varicose Veins on Healthcare Systems

The Economic Impact of Varicose Veins on Healthcare Systems

**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment of any medical condition.

Introduction: The Silent Burden of Varicose Veins

Varicose veins (VVs) and their more severe manifestation, Chronic Venous Insufficiency (CVI), represent a significant yet often underestimated public health challenge. Beyond the visible cosmetic concerns, these conditions are associated with a spectrum of debilitating symptoms, including pain, swelling, skin changes, and non-healing ulcers, profoundly impacting patients\' quality of life [1]. The pervasive nature of CVI and VVs extends beyond individual suffering, imposing a substantial economic burden on healthcare systems globally. This article delves into the multifaceted economic impact of varicose veins, examining direct and indirect costs, treatment landscapes, and disparities in care, with a focus on the implications for healthcare systems.

Understanding Varicose Veins and Chronic Venous Insufficiency

Varicose veins are enlarged, twisted veins, most commonly appearing in the legs and feet. They are a clinical manifestation of Chronic Venous Insufficiency (CVI), a progressive condition characterized by persistent, chronic ambulatory venous hypertension [2]. This hypertension arises from dysfunctional venous valves, leading to blood reflux and pooling in the lower extremities. The severity of CVI is systematically categorized by the Clinical-Etiology-Anatomic-Pathophysiology (CEAP) classification system, which ranges from C0 (no visible signs of venous disease) to C6 (active venous ulceration) [3].

Prevalence and Epidemiology

CVI is remarkably prevalent in developed countries. In the United States alone, over 25 million adults are affected by CVI, with approximately 6 million experiencing advanced stages of venous disease [1]. Global estimates suggest that CVI impacts 10-30% of the world\'s population [4]. The annual incidence of varicose veins is reported at 2.6% in women and 1.9% in men [1].

Numerous risk factors contribute to the development and progression of CVI and VVs. These include:

• **Obesity:** Defined as a body mass index >30 kg/m², obesity is consistently cited as a major risk factor [1].
• **Age and Gender:** Older age and female sex are frequently associated with higher prevalence, although the influence of gender is subject to ongoing research [1].
• **Pregnancy:** Hormonal changes and increased pressure on pelvic veins during pregnancy can exacerbate venous insufficiency.
• **Occupation:** Professions requiring prolonged standing or sitting are linked to an increased risk of developing varicose veins [4].

The Economic Burden on Healthcare Systems

The economic impact of varicose veins on healthcare systems is substantial, encompassing both direct and indirect costs.

Direct Costs

Direct costs are those directly attributable to the diagnosis, treatment, and management of CVI and VVs. These include:

• **Treatment Costs:** This category covers a wide array of expenses, from initial consultations and diagnostic imaging (e.g., duplex ultrasound) to various therapeutic interventions. Treatment options range from conservative management (compression therapy, medications) to more invasive procedures such as surgical stripping, endovenous thermal ablation (laser or radiofrequency), and sclerotherapy [5].
• **Hospitalizations and Physician Visits:** Patients with advanced CVI, particularly those with venous ulcers, often require frequent physician visits and may necessitate hospitalizations for wound care, infection management, or complex surgical procedures.
• **Medications and Wound Care:** Ongoing management of CVI symptoms and complications, especially venous leg ulcers, involves significant expenditure on prescription drugs, specialized dressings, and other wound care supplies.

Estimates of the annual cost for treating chronic venous disease in the US, including leg ulcers, range from $3 billion to over $4.9 billion annually [1, 6]. These figures underscore the considerable financial strain these conditions place on national healthcare budgets.

Indirect Costs

Indirect costs, though less tangible, represent a significant portion of the overall economic burden. These include:

• **Lost Productivity:** CVI symptoms, such as pain, edema, and ulceration, can lead to substantial functional impairment, resulting in missed workdays and reduced work productivity. Studies indicate that a considerable percentage of working adults miss work due to CVI-related issues [1]. In severe cases, CVI can lead to early disability, further contributing to economic losses.
• **Impact on Patient Quality of Life (QOL):** Beyond financial metrics, the chronic nature of CVI severely diminishes patients\' quality of life. Physical impairment from venous ulceration has been shown to be comparable to that experienced by individuals with congestive heart failure or chronic lung disease [5]. This reduction in QOL can lead to psychological distress, impacting overall well-being and societal participation.
• **Caregiver Burden:** Family members or other caregivers often bear the responsibility of assisting patients with advanced CVI, particularly those with chronic wounds. This informal care can lead to lost income, emotional stress, and reduced personal time for caregivers, representing another indirect cost to society.

Treatment Landscape and Associated Costs

The management of varicose veins and CVI involves a spectrum of approaches, each with varying costs and outcomes.

Conservative Management

Conservative therapies are typically the first-line treatment for many patients with symptomatic varicose veins. These include lifestyle modifications (exercise, weight management, leg elevation) and compression therapy (stockings or bandages) [5]. While generally less expensive than interventional procedures, the long-term adherence to and effectiveness of conservative measures can vary, and they may not prevent disease progression in all cases.

Interventional Therapies

For more advanced or symptomatic cases, interventional therapies are employed. These include:

• **Surgical Interventions:** Traditional surgical procedures, such as vein stripping and ligation, have been a mainstay of varicose vein treatment. While effective, they are more invasive and may involve longer recovery times and higher initial costs.
• **Endovenous Thermal Ablation:** Modern, minimally invasive techniques like laser ablation and radiofrequency ablation have become increasingly popular. These procedures use heat to close off diseased veins, offering good efficacy with shorter recovery periods [5].
• **Sclerotherapy:** This involves injecting a solution into the vein to cause it to scar and close. It is often used for smaller varicose veins and spider veins.

Despite the effectiveness of interventional treatments, recurrence rates can be high, with a significant percentage of patients requiring additional treatments within two years [5]. The cost of these procedures can range from hundreds to thousands of dollars per session, varying significantly based on the type of procedure, geographic location, and insurance coverage [7, 8].

Disparities in Care and Socioeconomic Factors

Racial and socioeconomic disparities significantly influence access to care and outcomes for patients with CVI. Studies have highlighted that certain racial groups and individuals from lower socioeconomic backgrounds may experience delayed diagnosis, limited access to specialized care, and poorer treatment outcomes [1]. These disparities not only exacerbate individual suffering but also contribute to the overall economic burden by increasing the prevalence of advanced disease and associated complications, requiring more intensive and costly interventions.

The Importance of Early Diagnosis, Treatment, and Prevention

Given the substantial economic and human costs associated with varicose veins, the importance of early diagnosis, timely treatment, and effective prevention strategies cannot be overstated. Early intervention can slow disease progression, prevent complications such as venous ulcers, and ultimately reduce the need for more complex and expensive treatments [1]. Screening programs, such as those established by the American Venous Forum, play a crucial role in identifying individuals at risk and facilitating early management [1]. Investing in preventative measures and promoting public awareness can lead to significant long-term cost savings for healthcare systems and improved health outcomes for patients.

Conclusion

Varicose veins and Chronic Venous Insufficiency represent a considerable economic challenge to healthcare systems worldwide. The direct costs associated with diagnosis, treatment, and ongoing care, coupled with the indirect costs of lost productivity and diminished quality of life, underscore the urgent need for comprehensive management strategies. By prioritizing early diagnosis, promoting accessible and effective treatments, and addressing socioeconomic disparities in care, healthcare systems can mitigate the economic burden of varicose veins and improve the lives of millions affected by this pervasive condition.

References

[1] Y. Kim, C.Y.M. Png, B.J. Sumpio, C.S. DeCarlo, A. Dua, "Defining the human and health care costs of chronic venous insufficiency," *Seminars in Vascular Surgery*, vol. 34, no. 1, pp. 59-64, Mar. 2021. [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S0895796721000077) [2] R. Van den Oever, "Socio-economic impact of chronic venous insufficiency. An underestimated public health problem," *International Angiology*, vol. 17, no. 4, pp. 280-285, Dec. 1998. [PubMed](https://pubmed.ncbi.nlm.nih.gov/9821029/) [3] B. Eklof et al., "Revision of the CEAP classification for chronic venous disorders: consensus statement," *Journal of Vascular Surgery*, vol. 40, no. 6, pp. 1248-1252, Dec. 2004. [4] Q.F. He et al., "Global prevalence and risk factors of varicose veins among healthcare workers: A systematic review and meta-analysis," *BMC Public Health*, vol. 25, no. 1, p. 417, May 2025. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12082987/) [5] R. Mallick et al., "Treatment Patterns and Outcomes in Patients with Varicose Veins," *American Health & Drug Benefits*, vol. 9, no. 8, pp. 455-465, Nov. 2016. [AHDB Online](https://ahdbonline.com/articles/treatment-patterns-and-outcomes-in-patients-with-varicose-veins) [6] P.J. Mallow et al., "Health Economic Analysis of Two-Layer Bandage System for Treatment of Chronic Venous Insufficiency," *Journal of Health Economics and Outcomes Research*, vol. 10, no. 1, pp. 1-10, Jan. 2023. [JHEOR](https://jheor.org/article/82159-health-economic-analysis-of-two-layer-bandage-system-for-treatment-of-chronic-venous-insufficiency) [7] "Varicose Vein Treatment: How Much Does It Cost?" *GoodRx*, Dec. 20, 2023. [GoodRx](https://www.goodrx.com/health-topic/dermatology/varicose-veins-treatment-removal-cost?srsltid=AfmBOooqtHhXaAutvw1esMM9ISoFKYpxO1g6nGLxRP4tNT-ghewBMZ0D) [8] "What is the Cost of Varicose Vein Treatment?" *Metro Vein Centers*, Dec. 5, 2025. [Metro Vein Centers](https://www.metroveincenters.com/blog/what-is-the-cost-of-varicose-vein-treatment)